PMID- 17638622
OWN - NLM
STAT- MEDLINE
DCOM- 20071018
LR  - 20171116
IS  - 1875-6263 (Electronic)
IS  - 1028-4559 (Linking)
VI  - 46
IP  - 2
DP  - 2007 Jun
TI  - Comparison of immunohistochemical and fluorescence in situ hybridization 
      assessment for HER-2/neu status in Taiwanese breast cancer patients.
PG  - 146-51
AB  - OBJECTIVE: Accurate diagnostic assessment of human epidermal growth factor 
      receptor-2 (HER-2) is essential and a prerequisite for appropriate application of 
      the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the 
      treatment of patients with breast cancer. Immunohistochemistry (IHC) is the most 
      widely applicable diagnostic modality in studying HER-2 status. Fluorescence in 
      situ hybridization (FISH) is also recognized as a modality in cases with an 
      equivocal IHC status (score, 2+). Some authors claimed that FISH alone is 
      sufficient. The aim of this study was to correlate the test results of IHC and 
      FISH for HER-2 gene amplification in breast cancer patients. FISH for 
      topoisomerase IIalpha (TOP2A) was also studied to see if deletion or 
      amplification of TOP2A has any supplementary role to HER-2, FISH and IHC. 
      MATERIALS AND METHODS: Assessment of HER-2 gene amplification and TOP2A gene 
      amplification/deletion was made by FISH analysis using the LSI TOP2A/HER-2/CEP 17 
      multicolor probe or the LSI HER-2/CEP dual color probe (Vysis, Downers Grove, IL, 
      USA) in formalin-fixed and paraffin-embedded tissue sections of 54 breast cancer 
      patients who were grouped into stages 1+, 2+ or 3+ based on IHC (HercepTest; 
      DakoCytomation, Carpinteria, CA, USA) observations. RESULTS: None of IHC 1+ 
      breast tumors was HER-2 FISH positive, but three of 18 (17%) IHC 3+ tumors were 
      HER-2 FISH negative. Overall, 53% of the IHC 2+ and 83% of the IHC 3+ cases were 
      HER-2 FISH positive. Only one case with IHC 3+ tumor that was HER-2 FISH positive 
      was found to have TOP2A amplification (>2.0) and no IHC 2+ cases were found to 
      have TOP2A amplification. There were no cases with TOP2A deletion (<0.8) in our 
      whole series. There were also no cases of HER-2 FISH negative tumors, but IHC 
      scored as 2+ or 3+ (0 of 10), to be found with TOP2A amplification. The 
      discordance rates by IHC were high (46.7% in IHC 2+, 16.7% in IHC 3+, 30.3% 
      overall in IHC 2+ or 3+). On the contrary, the discordance rates were zero if by 
      FISH. CONCLUSION: The current algorithm to use HER-2 FISH as a supplementary role 
      to IHC HercepTest 2+ may need some modifications according to the local setting. 
      TOP2A FISH adds little value to HER-2 FISH and IHC staining in our study.
FAU - Kuo, Shou-Jen
AU  - Kuo SJ
AD  - Department of Medical Research, Changhua Christian Hospital, Changhua, Taiwan.
FAU - Wang, Boris Bao-Tyan
AU  - Wang BB
FAU - Chang, Cheng-Shyong
AU  - Chang CS
FAU - Chen, Tze-Ho
AU  - Chen TH
FAU - Yeh, Kun-Tu
AU  - Yeh KT
FAU - Lee, Dong-Jay
AU  - Lee DJ
FAU - Yin, Pao-Lun
AU  - Yin PL
FAU - Chen, Ming
AU  - Chen M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Taiwan J Obstet Gynecol
JT  - Taiwanese journal of obstetrics & gynecology
JID - 101213819
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
MH  - Antigens, Neoplasm/genetics/metabolism
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/genetics/metabolism/pathology
MH  - Carcinoma, Lobular/genetics/metabolism/pathology
MH  - DNA Topoisomerases, Type II/genetics/metabolism
MH  - DNA-Binding Proteins/genetics/metabolism
MH  - Female
MH  - Gene Amplification
MH  - Gene Deletion
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Taiwan
EDAT- 2007/07/20 09:00
MHDA- 2007/10/19 09:00
CRDT- 2007/07/20 09:00
PHST- 2007/07/20 09:00 [pubmed]
PHST- 2007/10/19 09:00 [medline]
PHST- 2007/07/20 09:00 [entrez]
AID - S1028-4559(07)60008-4 [pii]
AID - 10.1016/S1028-4559(07)60008-4 [doi]
PST - ppublish
SO  - Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51. doi: 
      10.1016/S1028-4559(07)60008-4.